Similar articles

• Autoimmunity following neonatal tolerance to alloantigens: role of donor I-A and I-E molecules.

  Kramar G, Schurmans S, Berney M, Izui S, del Giudice G, Lambert PH. Kramar G, et al. J Autoimmun. 1995 Apr;8(2):177-92. doi: 10.1006/jaut.1995.0014. J Autoimmun. 1995. PMID: 7612147
• Polyclonal B cell activation by a B cell differentiation factor, B151-TRF2. III. B151-TRF2 as a B cell differentiation factor closely associated with autoimmune disease.

  Dobashi K, Ono S, Murakami S, Takahama Y, Katoh Y, Hamaoka T. Dobashi K, et al. J Immunol. 1987 Feb 1;138(3):780-7. J Immunol. 1987. PMID: 3543118
• Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity.

  Fu Y, Nathan DM, Li F, Li X, Faustman DL. Fu Y, et al. J Clin Invest. 1993 May;91(5):2301-7. doi: 10.1172/JCI116459. J Clin Invest. 1993. PMID: 8486790 Free PMC article.
• Role of MHC class I molecules in autoimmune disease.

  Singer DS, Mozes E, Kirshner S, Kohn LD. Singer DS, et al. Crit Rev Immunol. 1997;17(5-6):463-8. Crit Rev Immunol. 1997. PMID: 9419433 Review.
• B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.

  Eisenberg R, Albert D. Eisenberg R, et al. Nat Clin Pract Rheumatol. 2006 Jan;2(1):20-7. doi: 10.1038/ncprheum0042. Nat Clin Pract Rheumatol. 2006. PMID: 16932648 Review.